MedTrace Logo

Prognostic Value of Echocardiographic Parameters Based on Machine Learning Approach

NCT05772091 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2024-03-28

No results posted yet for this study

Summary

Transthyretin cardiac amyloidosis is an increasingly recognized cause of heart failure with preserved ejection fraction. Its diagnosis is currently based on a non-invasive method including biology and imaging. Still currently incurable, the evolution of this pathology is burdened by numerous comorbidities, including iterative hospitalizations for heart failure leading to death. The Machine Learning approach has already shown its efficiency in terms of diagnosis but its prognostic approach has not yet been studied.

Conditions

  • Transthyretin Cardiac Amyloidosis

Sponsors & Collaborators

  • Pr. Nicolas GIRERD

    lead OTHER

Principal Investigators

  • Nicolas GIRERD, MD, PhD · CHRU of Nancy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-29
Primary Completion
2024-03-31
Completion
2024-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05772091 on ClinicalTrials.gov